Title: A phase II trial of osimertinib and abemaciclib with a focus on non-small cell lung cancer patients with EGFR activating mutations with osimertinib resistance

Principal Investigator: Hatim Husain, MD, of University of California, San Diego

Description: Researchers are conducting a phase 2 trial to determine if adding abemaciclib to osimertinib can overcome resistance to osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC).


Continue Reading

Patients whose disease progressed on osimertinib treatment will receive abemaciclib at 150 mg twice a day and osimertinib at 80 mg daily. The primary outcome is progression-free survival at 6 months.

To be eligible for this study, patients must be 18 years of age or older and have NSCLC with an EGFR activating mutation. For a complete list of eligibility criteria, please see the reference. 

Status: Recruiting

This study is sponsored by University of California, San Diego in collaboration with Eli Lilly and Company.

Reference

ClinicalTrials.gov. Osimertinib and abemaciclib in EGFR mutant non-small cell lung cancer after osimertinib resistance. NCT04545710. Accessed July 25, 2022.